These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 31493351)

  • 41. CDDP-induced desmoplasia-like changes in oral cancer tissues are related to SASP-related factors induced by the senescence of cancer cells.
    Nishimura J; Morita Y; Tobe-Nishimoto A; Kitahira Y; Takayama S; Kishimoto S; Matsumiya-Matsumoto Y; Takeshita A; Matsunaga K; Imai T; Uzawa N
    Int Immunopharmacol; 2024 Jul; 136():112377. PubMed ID: 38838554
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development and functional analysis of an anticancer T-cell medicine with immune checkpoint inhibitory ability.
    Fujiwara K; Shigematsu K; Tachibana M; Okada N
    IUBMB Life; 2020 Aug; 72(8):1649-1658. PubMed ID: 32255257
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A senescence secretory switch mediated by PI3K/AKT/mTOR activation controls chemoprotective endothelial secretory responses.
    Bent EH; Gilbert LA; Hemann MT
    Genes Dev; 2016 Aug; 30(16):1811-21. PubMed ID: 27566778
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeting epiregulin in the treatment-damaged tumor microenvironment restrains therapeutic resistance.
    Wang C; Long Q; Fu Q; Xu Q; Fu D; Li Y; Gao L; Guo J; Zhang X; Lam EW; Campisi J; Sun Y
    Oncogene; 2022 Nov; 41(45):4941-4959. PubMed ID: 36202915
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Senescence-associated secretory factors induced by cisplatin in melanoma cells promote non-senescent melanoma cell growth through activation of the ERK1/2-RSK1 pathway.
    Sun X; Shi B; Zheng H; Min L; Yang J; Li X; Liao X; Huang W; Zhang M; Xu S; Zhu Z; Cui H; Liu X
    Cell Death Dis; 2018 Feb; 9(3):260. PubMed ID: 29449532
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Janus Silica Nanoparticle-Based Tumor Microenvironment Modulator for Restoring Tumor Sensitivity to Programmed Cell Death Ligand 1 Immune Checkpoint Blockade Therapy.
    Lin X; Li F; Guan J; Wang X; Yao C; Zeng Y; Liu X
    ACS Nano; 2023 Aug; 17(15):14494-14507. PubMed ID: 37485850
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Orphan nuclear receptor TLX promotes immunosuppression via its transcriptional activation of PD-L1 in glioma.
    Zhou J; Pei X; Yang Y; Wang Z; Gao W; Ye R; Zhang X; Liu J; Liu Z; Yang X; Tao J; Gu C; Hu W; Chan FL; Li X; Mao J; Wu D
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33858847
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeting SPINK1 in the damaged tumour microenvironment alleviates therapeutic resistance.
    Chen F; Long Q; Fu D; Zhu D; Ji Y; Han L; Zhang B; Xu Q; Liu B; Li Y; Wu S; Yang C; Qian M; Xu J; Liu S; Cao L; Chin YE; Lam EW; Coppé JP; Sun Y
    Nat Commun; 2018 Oct; 9(1):4315. PubMed ID: 30333494
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of Combination Strategies for the A
    Voronova V; Peskov K; Kosinsky Y; Helmlinger G; Chu L; Borodovsky A; Woessner R; Sachsenmeier K; Shao W; Kumar R; Pouliot G; Merchant M; Kimko H; Mugundu G
    Front Immunol; 2021; 12():617316. PubMed ID: 33737925
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells.
    Tu J; Xu H; Ma L; Li C; Qin W; Chen X; Yi M; Sun L; Liu B; Yuan X
    Theranostics; 2022; 12(2):747-766. PubMed ID: 34976211
    [No Abstract]   [Full Text] [Related]  

  • 51. Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation.
    Wu M; Huang Q; Xie Y; Wu X; Ma H; Zhang Y; Xia Y
    J Hematol Oncol; 2022 Mar; 15(1):24. PubMed ID: 35279217
    [TBL] [Abstract][Full Text] [Related]  

  • 52. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.
    Mariathasan S; Turley SJ; Nickles D; Castiglioni A; Yuen K; Wang Y; Kadel EE; Koeppen H; Astarita JL; Cubas R; Jhunjhunwala S; Banchereau R; Yang Y; Guan Y; Chalouni C; Ziai J; Şenbabaoğlu Y; Santoro S; Sheinson D; Hung J; Giltnane JM; Pierce AA; Mesh K; Lianoglou S; Riegler J; Carano RAD; Eriksson P; Höglund M; Somarriba L; Halligan DL; van der Heijden MS; Loriot Y; Rosenberg JE; Fong L; Mellman I; Chen DS; Green M; Derleth C; Fine GD; Hegde PS; Bourgon R; Powles T
    Nature; 2018 Feb; 554(7693):544-548. PubMed ID: 29443960
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The senescence-associated secretory phenotype is potentiated by feedforward regulatory mechanisms involving Zscan4 and TAK1.
    Zhang B; Fu D; Xu Q; Cong X; Wu C; Zhong X; Ma Y; Lv Z; Chen F; Han L; Qian M; Chin YE; Lam EW; Chiao P; Sun Y
    Nat Commun; 2018 Apr; 9(1):1723. PubMed ID: 29712904
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity.
    Tanegashima T; Togashi Y; Azuma K; Kawahara A; Ideguchi K; Sugiyama D; Kinoshita F; Akiba J; Kashiwagi E; Takeuchi A; Irie T; Tatsugami K; Hoshino T; Eto M; Nishikawa H
    Clin Cancer Res; 2019 Aug; 25(15):4808-4819. PubMed ID: 31076547
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune response.
    Luo M; Fu L
    Oncotarget; 2016 May; 7(20):29794-803. PubMed ID: 26919108
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.
    Antonios JP; Soto H; Everson RG; Moughon D; Orpilla JR; Shin NP; Sedighim S; Treger J; Odesa S; Tucker A; Yong WH; Li G; Cloughesy TF; Liau LM; Prins RM
    Neuro Oncol; 2017 Jun; 19(6):796-807. PubMed ID: 28115578
    [TBL] [Abstract][Full Text] [Related]  

  • 57. YY1 regulates cancer cell immune resistance by modulating PD-L1 expression.
    Hays E; Bonavida B
    Drug Resist Updat; 2019 Mar; 43():10-28. PubMed ID: 31005030
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Synergistic Antitumor Effect on Bladder Cancer by Rational Combination of Programmed Cell Death 1 Blockade and CRISPR-Cas9-Mediated Long Non-Coding RNA Urothelial Carcinoma Associated 1 Knockout.
    Zhen S; Lu J; Chen W; Zhao L; Li X
    Hum Gene Ther; 2018 Dec; 29(12):1352-1363. PubMed ID: 30457360
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Carboplatin and programmed death-ligand 1 blockade synergistically produce a similar antitumor effect to carboplatin alone in murine ID8 ovarian cancer model.
    Zhu X; Xu J; Cai H; Lang J
    J Obstet Gynaecol Res; 2018 Feb; 44(2):303-311. PubMed ID: 29171115
    [TBL] [Abstract][Full Text] [Related]  

  • 60. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
    Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
    Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.